Our study demonstrates that ATG9A deficiency sensitizes cancer cells to macrophage-mediated killing, particularly in the presence of antitumor antibodies or CAR, which provide target specificity for cytotoxic macrophages. The gene discussed is ATG9A; the disease is cancer.